References
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:https://doi.org/10.3322/caac.20107.
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209–249. doi:https://doi.org/10.3322/caac.21660.
- Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393(10167):169–182. doi:https://doi.org/10.1016/S0140-6736(18)32470-X.
- Peters WR, Liu PY, Barrett RN, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18(8):1606–1613. doi:https://doi.org/10.1200/JCO.2000.18.8.1606.
- Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1990;38(3):352–357. doi:https://doi.org/10.1016/0090-8258(90)90072-S.
- Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol. 1999;73(2):177–183. doi:https://doi.org/10.1006/gyno.1999.5387.
- Rotman M, Sedlis A, Piedmonte MR, et al. A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 2006;65(1):169–176. doi:https://doi.org/10.1016/j.ijrobp.2005.10.019.
- Cibula D, Abu-Rustum NR, Fischerova D, et al . Surgical treatment of “intermediate risk” lymph node negative cervical cancer patients without adjuvant radiotherapy – a retrospective cohort study and review of the literature. Gynecol Oncol. 2018;151(3):438–443. doi:https://doi.org/10.1016/j.ygyno.2018.10.018.
- Nakamura K, Kitahara Y, Satoh T, et al. Analysis of the effect of adjuvant radiotherapy on outcomes and complications after radical hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors (GOTIC Study). World J Surg Onc. 2016;14(1):173. doi:https://doi.org/10.1186/s12957-016-0931-4.
- Akilli H, Tohma YA, Bulut AN, et al . Comparison of no adjuvant treatment and radiotherapy in early-stage cervical carcinoma with intermediate risk factors . Int J Gynaecol Obstet. 2020;149(3):298–302. doi:https://doi.org/10.1002/ijgo.13147.
- Yang K, Park W, Huh SJ, Bae D, Kim B, Lee J. Clinical outcomes in patients treated with radiotherapy after surgery for cervical cancer. Radiat Oncol J. 2017;35(1):39–47. doi:https://doi.org/10.3857/roj.2016.01893.
- Salani R, Backes FJ, Fung Kee Fung M, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: society of gynecologic oncologists recommendations. Am J Obstet Gynecol. 2011;204(6):466–478. doi:https://doi.org/10.1016/j.ajog.2011.03.008.
- Roche WD, Norris HJ. Microinvasive carcinoma of the cervix. The significance of lymphatic invasion and confluent patterns of stromal growth. Cancer-Am Cancer Soc. 1975;36(1):180–186. doi:https://doi.org/10.1002/1097-0142(197507)36:1<180::AID-CNCR2820360116>3.0.CO;2-K.
- Boyce J, Fruchter RG, Nicastri AD, Ambiavagar PC, Reinis MS, Nelson JJ. Prognostic factors in stage I Carcinoma of the cervix. Gynecol Oncol. 1981;12(2):154–165. doi:https://doi.org/10.1016/0090-8258(81)90145-1.
- Rotman M, Pajak TF, Choi K, et al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20. JAMA. 1995;274(5):387–393. doi:https://doi.org/10.1001/jama.274.5.387.
- van Nagell JJ, Donaldson ES, Wood EG, Parker JJ. The significance of vascular invasion and lymphocytic infiltration in invasive cervical cancer. Cancer-Am Cancer Soc. 1978;41(1):228–234. doi:https://doi.org/10.1002/1097-0142(197801)41:1<228::AID-CNCR2820410131>3.0.CO;2-6.
- Boyce JG, Fruchter RG, Nicastri AD, et al. Vascular invasion in Stage I carcinoma of the cervix. Cancer-Am Cancer Soc. 1984;53(5):1175–1180. doi:https://doi.org/10.1002/1097-0142(19840301)53:5<1175::AID-CNCR2820530524>3.0.CO;2-Y.
- Chung CK, Nahhas WA, Stryker JA, Curry SL, Abt AB, Mortel R. Analysis of factors contributing to treatment failures in stages IB and IIA carcinoma of the cervix. Am J Obstet Gynecol. 1980;138(5):550–556. doi:https://doi.org/10.1016/0002-9378(80)90285-9.
- Eifel PJ, Morris M, Wharton JT, Oswald MJ. The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 1994;29(1):9–16. doi:https://doi.org/10.1016/0360-3016(94)90220-8.
- Dueñas-González A, Zarbá JJ, Patel F, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. JCO. 2011;29(13):1678–1685. doi:https://doi.org/10.1200/JCO.2009.25.9663.
- Tsuji K, Shimada M, Takahashi F, et al. Clinico-pathological characteristics of patients with stage IB1-IB2 (FIGO 2018) uterine cervical cancer: a nationwide study in Japan. Int J Clin Oncol. 2021;26(8):1541–1552. doi:https://doi.org/10.1007/s10147-021-01938-4.
- Nie J, Wu Q, Yan A, Wu Z. Impact of different therapies on the survival of patients with stage I-IIA cervical cancer with intermediate risk factors. Ann Transl Med. 2021;9(2):142–142. doi:https://doi.org/10.21037/atm-20-7679.
- Pieterse QD, Trimbos JB, Dijkman A, et al. Postoperative radiation therapy improves prognosis in patients with adverse risk factors in localized, early-stage cervical cancer: a retrospective comparative study. Int J Gynecol Cancer. 2006;16(3):1112–1118. doi:https://doi.org/10.1111/j.1525-1438.2006.00600.x.
- Schorge JO, Molpus KL, Koelliker D, Nikrui N, Goodman A, Fuller AJ. Stage IB and IIA cervical cancer with negative lymph nodes: the role of adjuvant radiotherapy after radical hysterectomy. Gynecol Oncol. 1997;66(1):31–35. doi:https://doi.org/10.1006/gyno.1997.4691.
- Sagi-Dain L, Abol-Fol S, Lavie O, Sagi S, Ben Arie A, Segev Y. Cervical cancer with intermediate risk factors: is there a role for adjuvant radiotherapy? A systematic review and a meta-analysis. Gynecol Obstet Invest. 2019;84(6):606–615. doi:https://doi.org/10.1159/000501683.
- Ryu SY, Kim MH, Nam BH, et al. Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy: a Korean Gynecologic Oncology Group study. Br J Cancer. 2014;110(2):278–285. doi:https://doi.org/10.1038/bjc.2013.716.
- Valenti G, Vitale SG, Tropea A, Biondi A, Laganà AS. Tumor markers of uterine cervical cancer: a new scenario to guide surgical practice? Updates Surg. 2017;69(4):441–449. doi:https://doi.org/10.1007/s13304-017-0491-3.